Neuland Laboratories Ltd Share Price (NEULANDLAB)

Neuland Laboratories Ltd's P/E Ratio of 31x Raises Concerns - 19 Apr, 2024

Despite a surge in stock price, Neuland Laboratories' P/E ratio of 31x is concerning as it matches the median P/E in India. Analysts predict a decrease in earnings by 0.6% next year, but investors remain optimistic. The outlook for the company appears poor and unless conditions improve, prices may not be reasonable.

Neuland Laboratories Shares Indicate Near-Term Bullishness - 16 Apr, 2024

Shares of Neuland Laboratories are up by 34% on a year-to-date basis and have delivered returns in excess of 15% in April, according to seasonality. The shares are trading above their 10-day and 20-day SMA, indicating near-term bullishness.

Neuland Laboratories Reports Strong EPS Growth and Revenue Increase - 15 Apr, 2024

Neuland Laboratories has reported a significant increase in earnings per share (EPS) from ₹78.52 to ₹247 over the last year, along with revenue growth and improved EBIT margins. Insiders own 37% of shares. Consider adding Neuland Laboratories to your watchlist.

Goldman Sachs Initiates Coverage on Neuland Labs with Buy Recommendation - 13 Apr, 2024

Global brokerage firm Goldman Sachs has initiated coverage on Neuland Laboratories Limited with a buy recommendation and a target price of Rs. 9,100 per share, indicating a potential upside of nearly 47%. The company's revenue from operations increased by 46.1% YoY in Q3 FY23-24, and the net profit also rose significantly. Multiple catalysts were highlighted for Neuland Labs, including an improved biotech funding environment, new capacity at unit-3 coming online by the end of FY25, and commercialisation of a large molecule in FY26 or FY27.

Goldman Sachs Initiates Buy Rating on Neuland Laboratories Stock - 12 Apr, 2024

Brokerage firm Goldman Sachs has initiated a buy rating on Neuland Laboratories Ltd, projecting a price target of Rs 9,100 per share. The stock gained over 8% in response. Although the brokerage sees challenges to growth in the current financial year, it highlights multiple catalysts for future growth.

Neuland Laboratories Reports Strong Q3FY24 Results - 03 Apr, 2024

Neuland Laboratories has reported a 46.09% YoY growth in revenue from operations, accompanied by profits of Rs. 81 Crores. The stock has delivered multi-bagger returns of 236% in a year and has a low PEG ratio of 0.38.

Neuland Laboratories Ltd Stock Sees Impressive Growth - 25 Mar, 2024

Over the past three months, Neuland Laboratories' stock has increased by 25%, with a ROE of 28% and substantial net income growth. However, analyst forecasts predict a slowdown in future earnings growth.

Neuland Labs Rises on Successful USFDA Inspection - 22 Mar, 2024

Neuland Laboratories Ltd's stock rose almost 6% after the company informed the exchanges that the US Food and Drug Administration (FDA) completed an inspection in Hyderabad without any observations. The company reported a consolidated net profit of Rs 81.39 crore in Q3 FY24, steeply higher than Rs 30.55 crore posted in Q3 FY23.